Dallas, Texas, October 30, 2025 — Lantern Pharma Inc. (NASDAQ: LTRN) announced it will present two cutting-edge AI-driven drug-development platforms at the inaugural AI for Biology and Medicine Symposium hosted by the University of North Texas. The company’s machine-learning technologies, predictBBB.ai and LBx-AI, are designed to dramatically reduce the time and cost of developing oncology therapies — from months to days — while improving success rates in clinical translation.
Science Significance
Lantern Pharma’s predictBBB.ai and LBx-AI platforms represent a new era of AI-integrated drug discovery. LBx-AI, meanwhile, applies machine learning to liquid-biopsy data, predicting cancer treatment response with 86 % accuracy and discovering novel biomarker pathways. These platforms allow researchers to uncover complex molecular relationships missed by traditional analysis, representing a transformative leap in computational oncology and precision medicine. predictBBB.ai achieves 94.1 % accuracy in predicting blood-brain-barrier permeability, enabling pharmaceutical teams to screen over 200,000 molecules within a week.
Regulatory Significance
The development of validated AI models for drug-candidate optimization and biomarker identification supports compliance with cGxP data-integrity principles. By enabling reproducible, auditable computational workflows, Lantern’s platforms align with the evolving regulatory landscape for AI-assisted drug discovery under FDA and EMA guidelines. Their performance in blind validations and large-scale datasets offers the data robustness and traceability required for future inclusion in regulatory submissions for oncology programs.
Business Significance
Advertisement
This presentation positions Lantern Pharma as a leader in AI-powered oncology innovation. The company’s commercially ready platforms can be accessed by partners and collaborators through open-access services, providing scalable revenue opportunities and strengthening industry partnerships. By compressing experimental timelines and reducing development costs, Lantern enhances its competitive advantage and expands its influence in the growing AI-pharma ecosystem. The commercial deployment of these models reinforces investor confidence in Lantern’s RADR® platform, the company’s integrated AI-drug-development ecosystem.
Patients’ Significance
For patients battling cancer, these technologies hold the potential to speed access to life-saving therapies. AI-enabled platforms reduce the time between target identification and clinical testing, meaning that new oncology drugs could reach trials and approval faster. LBx-AI’s ability to predict treatment response and discover hidden biomarkers can guide personalized therapy choices, improve patient outcomes, and reduce the trial-and-error burden of cancer treatment.
Policy Significance
Lantern’s initiative aligns with the policy shift toward AI adoption in biomedical research, emphasizing transparency, model validation, and equitable access to computational tools. The company’s decision to make both platforms open-access for collaborators reflects an ethical commitment to democratizing innovation, consistent with global policy efforts to accelerate digital transformation in life sciences. This development supports national AI-in-health strategies promoting efficiency, reproducibility, and innovation in regulated drug-discovery environments.
Lantern Pharma’s presentation of its AI-driven platforms marks a milestone in the convergence of artificial intelligence, computational biology, and oncology research. By transforming complex molecular data into actionable clinical insights, the company exemplifies the future of data-driven, precision-based biopharmaceutical development. With its predictBBB.ai and LBx-AI systems now commercially deployed, Lantern sets a benchmark for how AI and cGxP standards can harmonize to advance faster, safer, and more effective cancer therapies worldwide.
Source: Lantern Pharma Inc. press release
